have equal contribution in this study.
Introduction
The medial prefrontal cortex (mPFC) is strongly involved in cognitive, emotional and motivational processes and in regulation of responses to aversion (Laviolette et al., 2005; Resstel et al., 2006; Wang et al., 2009; Gilmartin et al., 2013; Gilmartin et al., 2014; Jiang et al., 2014) and pain (Baulmann et al., 2000; Luongo et al., 2013; Okine et al., 2016) . The mPFC comprises a number of subregions that can be differentiated by anatomical connectivity, cytoarchitecture and function. In rodents, the infralimbic (IfL) and prelimbic (PrL) subregions of the mPFC have been shown to differentially affect acquisition, consolidation and expression of contextually conditioned fear (Vidal-Gonzalez et al., 2006; Corcoran and Quirk, 2007; Sierra-Mercado et al., 2011; Sharpe and Killcross, 2014; Almada et al., 2015) . Roles for the PrL in fear-induced antinociception (Freitas et al., 2013) and formalin-induced conditioned place avoidance (Jiang et al., 2014) have also been demonstrated. The anterior cingulate cortex (ACC) is a subregion of the mPFC involved in the modulation of fear behaviour (Einarsson et al., 2015) , cognitive-affective component of pain (Johansen et al., 2001) and in top-down descending modulation of pain (Fuchs et al., 2014) . The ACC is connected reciprocally with both the PrL and the IfL and may play a role in modulating their output (Vertes, 2002) . Despite the evidence for a role of the IfL, PrL and ACC in fear-related and pain-related behaviour, there is a paucity of studies comparing these three subregions of the mPFC with respect to their role in fear-pain interactions, which we sought to address here.
Specifically, we investigated the role of the endogenous cannabinoid (endocannabinoid) system within subregions of the mPFC in the expression of formalin-evoked nociceptive tone, fear-conditioned analgesia (FCA) and conditioned fear in the presence of nociceptive tone. The endocannabinoid system consists of cannabinoid CB 1 (Devane et al., 1988; Matsuda et al., 1990) and CB 2 (Munro et al., 1993) receptors, their endogenous ligands (or endocannabinoids), the two best characterized being N-arachidonoylethanolamide [anandamide (AEA)] and 2-arachidonoyl glycerol (Devane et al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995) , and the enzymes responsible for the synthesis and degradation of the endocannabinoids. FCA is the robust suppression of nociceptive behaviour during or following expression of classical Pavlovian conditioned fear (Ford and Finn, 2008; Butler and Finn, 2009 ). Our previous research has implicated the PFC in the expression of FCA in rats (Butler et al., 2011) . Moreover, we and others have demonstrated a key role for the endocannabinoid system in FCA (Finn et al., 2003; Finn et al., 2004; Roche et al., 2007; Butler et al., 2008; Ford and Finn, 2008; Butler and Finn, 2009; Ford et al., 2011; Olango et al., 2012; Rea et al., 2013; Olango et al., 2014; Corcoran et al., 2015) and unconditioned stress-induced analgesia Suplita et al., 2005; Connell et al., 2006; Guindon and Hohmann, 2009 ). These studies have highlighted the importance of the endocannabinoid system in discrete brain regions including the amygdala (Rea et al., 2013) , hippocampus (Ford et al., 2011) and periaqueductal grey (Olango et al., 2012) , all of which are connected anatomically to the mPFC. Components of the endocannabinoid system, including CB 1 receptors and the anandamide-catabolizing enzyme fatty acid amide hydrolase (FAAH), are highly expressed in the mPFC (Herkenham et al., 1991; Mailleux and Vanderhaeghen, 1992; Tsou et al., 1998; Egertova et al., 2003) . Interestingly, Freitas et al. (2013) have demonstrated that innate, unconditioned fear-induced antinociception arising from blockade of GABA A receptors in the ventromedial and dorsomedial hypothalamus is attenuated by microinjection of the CB 1 receptor antagonist/inverse agonist AM251 into the PrL. However, no studies to date have compared the role of the endocannabinoid system in the PrL, IfL and ACC in pain suppression arising from conditioned fear (FCA), and this was the primary aim of the present study.
We tested the hypothesis that the endocannabinoid system in the PrL, IfL and ACC differentially modulates FCA and expression of fear in the presence of formalin-evoked nociceptive tone. To this end, we investigated the effects of local intra-PrL, intra-IfL and intra-ACC microinjections of the FAAH inhibitor, URB597 and the CB 1 receptor antagonist/inverse agonist, AM251, alone or in combination, on formalin-evoked nociceptive behaviour, FCA and expression of fear in the presence of formalin-evoked nociceptive tone in rats. Elucidation of the role of the endocannabinoid system in different subregions of the mPFC in fear-pain interactions may facilitate increased understanding and improved treatment of pain-related and fear-related disorders and their comorbidity.
Methods

Animals
All animal care and experimental procedures were approved by the Animal Care and Research Ethics Committee, National University of Ireland, Galway, and the work carried out under licence from the Irish Department of Health and Children, in compliance with the European Communities Council directives 86/609 and 2010/63 and conformed to the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . A total of 280 male Lister-hooded rats (260-350 g on day of behavioural testing; Charles River, Margate, Kent, UK) were used. Animals were housed 3-4 per cage before surgery and singly thereafter in plastic bottomed cages (L: 45 × H: 20 × W: 20 cm) with wood shavings as bedding. They were maintained at a constant temperature (22 ± 2°C) under standard lighting conditions (12:12 h light-dark, lights on from 0800 to 2000 h). Experiments were carried out during the light phase between 0800 and 1700 h. Food (14% HarlanTeklad-2014 Maintenance Diet, Harlan Laboratories, Belton, Loughborough, UK) and water were available ad libitum.
Cannulae implantation
Animals were left to acclimatize for 4-8 days after delivery before surgery. Stainless steel guide cannulae (5 mm length, 22G; Plastics One Inc., Roanoke, VA, USA) were stereotaxically implanted bilaterally 1 mm above the right and left IfL [anteroposterior (AP) + 2 mm relative to bregma, medial lateral (ML) ± 1.5 mm relative to bregma and at a 12 o angle and dorsal ventral (DV) -3.6 mm from dura, toothbar set at À3 mm], or PrL (AP + 2.4 mm relative to bregma, ML ± 1.5 mm mPFC endocannabinoids and fear-pain interactions relative to bregma and at a 12 o angle and DV -2.3 mm from dura, toothbar set at À3 mm) or ACC (AP + 1 mm relative to bregma, ML ± 1.3 mm at a 12 o angle and DV -1.3 mm from dura, toothbar set at À3 mm) (Paxinos and Watson, 1998) s.c.; Baytril; Bayer Ltd., Dublin, Ireland), were administered before surgery to manage post-operative pain and to prevent infection respectively. Following cannulae implantation, the rats were housed singly and administered enrofloxacin (2.5 mg·kg À1 s.c.) for a further 3 days. Rats were allowed to recover for at least 6 days prior to experimentation. During this period, the rats were handled daily, stylets checked and their body weight and general health monitored on a daily basis.
Drug preparation
On test days, stock solutions of 4 mM AM251 and 0.2 mM URB597 were prepared in 100% DMSO vehicle (VEH). For bilateral intra-PrL, intra-IfL and intra-ACC microinjections, AM251 and URB597 were diluted to a concentration of 2 and 0.1 mM in 100% DMSO VEH, respectively, while the combination was prepared by adding equal volumes of the stock 4 mM AM251 and 0.2 mM URB597. These doses of URB597 and AM251 are based on previous work carried out by our laboratory and evidence from the literature in rat models of pain and fear (Laviolette and Grace, 2006; de Novellis et al., 2008; Lisboa et al., 2010; Ebrahimzadeh and Haghparast, 2011; Ford et al., 2011; Olango et al., 2012; Freitas et al., 2013; Rea et al., 2014a) . A solution of 2.5% formalin (Sigma-Aldrich) was prepared from a 37% stock solution diluted with 0.9% sterile saline.
Experimental procedures
The FCA paradigm was essentially as described previously (Finn et al., 2004; Roche et al., 2007; Butler et al., 2008; Rea et al., 2009) . In brief, it consisted of two phases, conditioning and testing, occurring 24 h apart. On the conditioning day, rats were placed in a Perspex fear-conditioning/observation chamber (30 × 30 × 30 cm), and after 15 s, they received the first of 10 footshocks (0.4 mA, 1 s duration; LE85XCT Programmer and Scrambled Shock Generator; Linton Instrumentation, Norfolk, UK) spaced 60 s apart. Fifteen seconds after the last footshock, rats were returned to their home cage.
Controls not receiving footshock were exposed to the chamber for an equivalent 9.5 min period. Three experiments, all using a different cohort of rats, were carried out involving microinjections of URB597, AM251, URB597 + AM251 (combination) or VEH into the IfL, PrL or ACC respectively ( Figure 1 ). The conditioning phase for these experiments was carried out as outlined above. The test phase commenced 23.5 h later when the rats received an intraplantar injection of 50 μL formalin (2.5% formaldehyde solution prepared in sterile saline) into the right hindpaw under brief isoflurane anaesthesia (2-3% in O 2 ; 0.5 L·min À1 ). Fifteen minutes post-formalin injection, rats received bilateral intra-IfL, intra-PrL or intra-ACC microinjections of VEH (100% DMSO), 2 mM AM251, 0.1 mM URB597 or the combination of 2 mM AM251 with 0.1 mM URB597 in an injection volume of 0.3 μL over a 60 s time interval using an injection pump, a 1 μL Hamilton syringe and polyethylene tubing connected to a stainless steel injector with 1 mm protrusion beyond the guide cannula (28G; Plastics One Inc.). Immediately following the intracerebral microinjections, rats were returned to their home cages for 15 min prior to being placed into the same Perspex arenas in which they had been conditioned. A video camera located beneath the observation chamber was used to monitor animal behaviour. The video feed was recorded onto DVD for 30 min. The 30-60 min post-formalin
Figure 1
Diagram of the experimental paradigm, treatment groups and timeline.
interval was chosen on the basis of previous studies demonstrating that formalin-evoked nociceptive behaviour is stable over this time period, is endocannabinoid mediated and is subject to supraspinal modulation (Finn et al., 2004; Ford et al., 2011; Olango et al., 2012; Rea et al., 2011; Roche et al., 2010) . At the end of the test phase (60 min post-formalin injection), rats were killed by decapitation, and an intracerebral microinjection of Fastgreen dye (0.5 μL of 1% solution) was given for subsequent histological confirmation of the microinjection sites. The brains were then removed, snap-frozen on dry ice and stored at À80°C.
Formalin-induced oedema was assessed by measuring the change in the diameter of the right hindpaw immediately before, and 60 min after, formalin administration, using Vernier callipers.
This design resulted in eight experimental groups (starting n = 11-12 per group for surgery; final n after removal of outliers where the cannula placements were inaccurate or injections were suboptimal are shown in Table 1 ).
Behavioural analysis
Ethovision XT 7.0 software package (Noldus, Wageningen, The Netherlands) was used to analyse behaviour, allowing for continuous event recording over each 30 min trial. The behaviours assessed (by an experimenter blind to treatment) were duration of freezing (defined as the cessation of all visible movement except that necessary for breathing) as a measure of fear-related behaviour and nociceptive behaviours [composite pain score (CPS)] as described previously (Finn et al., 2004; Finn et al., 2006; Butler et al., 2008) . Nociceptive behaviours were measured using the weighted composite pain scoring technique (Watson et al., 1997) . Nociceptive behaviours are divided into two types according to this method; the first (pain 1) is the time spent elevating the formalin-injected paw without contact with any other surface. The second (pain 2) is the time spent holding, licking, biting, shaking or flinching the formalin-injected paw. The CPS equation is given as composite pain score [CPS = (duration of pain 1 + 2 × duration of pain 2) (total duration of analysis period)] (Watson et al., 1997) . The EthoVision system automatically tracked total distance moved as a measure of locomotor activity.
Histological verification of intracerebral microinjection sites
The sites of intracerebral microinjection were determined prior to data analysis. Brain sections (30 μm thickness) marked with Fastgreen dye mark were collected using a cryostat (Microm, Thermo Fisher Scientific, Walldorf, Germany), mounted on gelatinized glass slides and counterstained with cresyl violet to locate the precise position of microinjection sites under light microscopy.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Rats were randomly assigned to experimental groups, and the sequence of testing was randomized throughout the experiment. Previous published studies and power analysis suggested that when using ANOVA, the sample sizes used would yield sufficient power to reliably detect differences in the means between groups with sufficient power (i.e. >90%). Results are expressed as group means ± SEM. The IBM SPSS statistical software package (SPSS v23.0 for Microsoft Windows, Chicago, IL, USA) was used to analyse all data. Normality and homogeneity of variance were assessed using Shapiro-Wilk's and Levene's test respectively. Paw oedema data were analysed using a paired Student's t-test. Time course behavioural data were analysed by two-way repeated measures ANOVA with time as the within-subjects factor and fear conditioning and drug treatment as the between-subjects factors. Post hoc pairwise comparisons were made with Tukey's test when appropriate. Differences between group means were considered significant when P < 0.05.
Materials
Formalin (37% formaldehyde solution), DMSO and URB597 were purchased from Sigma-Aldrich, Dublin, Ireland. AM251 was purchased from Abcam plc, Cambridge, UK.
Table 1
Summary of experimental groups and final n number per group in experiments 1 (IfL), 2 (PrL) and 3 (ACC)
Group
Conditioning Formalin i.pl. Drug/VEH IfL (n) P r L( n) A C C( n) mPFC endocannabinoids and fear-pain interactions
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Histological verification of microinjection sites
After histological verification, 75% of the microinjections were found to be within the borders of both the left and the right IfL, 84% in the PrL and 78% in the ACC. The remaining microinjections were placed in the corpus callosum, or outside the borders of the IfL, PrL or ACC respectively. Only data from rats where intracerebral injections were accurately placed in both the left and the right IfL, PrL or ACC have been included in this paper (Figures 2A, B, 3A , B and 4A, B).
Effects of intra-mPFC administration of AM251, URB597 or URB597 + AM251 on formalin-evoked nociceptive behaviour and FCA
Intraplantar injection of formalin increased right hindpaw diameter (indicative of oedema) in each of the three studies Figure 2 (A, B) Diagram of the confirmed microinjection sites of all animals with guide cannulae in the left and right IfL.
(IfL PrL and ACC), and produced robust licking, biting, shaking, flinching and elevation of the injected right hindpaw. In the IfL study, two-way repeated measures ANOVA revealed a significant effect of fear conditioning, treatment and fear conditioning * treatment on CPS over the course of the 30 min testing period ( Figure 5A ). There was also a significant effect of time, time * fear conditioning, time * treatment and time * fear conditioning * treatment . Further post hoc analysis with Tukey's test revealed that fear-conditioned (FC) VEH-treated rats displayed significantly less formalinevoked nociceptive behaviour compared with non-fearconditioned (NFC) VEH-treated rats in the first 10 min of the testing period, confirming the expression of FCA. This FCA was significantly attenuated by intra-IfL administration of either AM251 or URB597 alone and a non-significant trend for a similar attenuation when both drugs were coadministered. Intra-IfL administration of these drugs had no significant effect on formalin-evoked nociceptive behaviour in NFC rats ( Figure 5A ).
In the PrL study, similar analysis revealed a significant effect of fear conditioning but not treatment or fear conditioning * treatment on CPS over the course of the 30 min testing period ( Figure 6A ). There was also a significant effect of time and time * fear conditioning but Further post hoc analysis with Tukey's test revealed that FC VEH-treated rats displayed significantly less formalin-evoked nociceptive behaviour compared with NFC VEH-treated rats in the first 10 min of the testing period, confirming the expression of FCA. This FCA was significantly attenuated by intra-PrL administration of AM251 but not by URB597 or co-administration of URB597 and AM251. Indeed, FC rats that received intra-PrL URB597 (but not URB597 + AM251) had significantly lower formalin-evoked nociceptive behaviour than NFC counterparts over the first 20 min of the trial, suggesting that URB597 prolonged the expression of FCA relative to VEH-treated FC rats in which significant FCA was observed in the first 10 min only. This URB597-induced prolongation of FCA was not observed in rats cotreated with URB597 and AM251. Intra-PrL administration of these drugs had no significant effect on formalin-evoked nociceptive behaviour in NFC rats ( Figure 6A ).
In the ACC study, there was a significant effect of fear conditioning but not treatment or fear conditioning * treatment on CPS over the course of the 30 min testing period ( Figure 7A ). There was also a significant effect of time and time * fear conditioning but not time * treatment or time * fear conditioning * treatment. Further post hoc analysis with Tukey's test revealed that FC VEH-treated rats displayed significant less formalin-evoked nociceptive behaviour compared with NFC VEH-treated rats in the first 20 min of the testing period, confirming the expression of FCA. Intra-ACC Figure 5 (A) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the IfL on formalin-evoked nociceptive behaviour in rats over the full 30 min testing period subdivided into 10 min time bins. (B) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the IfL on the duration of freezing in formalin-injected rats over the full 30 min testing period, subdivided into 10 min time bins. (C) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 +-AM251 directly into the IfL on the distance moved (cm) in formalin-injected rats over the full 30 min testing period, subdivided into 10 min time bins. All data are expressed as mean ± SEM. *P < 0.05, significantly different from NFC; # P < 0.05, significantly different from FC VEH.
Figure 6
(A) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the PrL on formalin-evoked nociceptive behaviour in rats over the full 30 min testing period subdivided into 10 min time bins. (B) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the PrL on the duration of freezing in formalin-injected rats over the full 30 min testing period, subdivided into 10 min time bins. (C) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the PrL on the distance moved (cm) in formalin-injected rats over the full 30 min testing period, subdivided into 10 min time bins. All data are expressed as mean ± SEM. *P < 0.05, significantly different from NFC; # P < 0.05, significantly different from FC VEH.
administration of AM251 or URB597, alone or in combination, had no significant effect on the expression of formalinevoked nociceptive behaviour per se or FCA ( Figure 7A ).
Data from these sets of experiments are summarised in Table 2 .
Effects of intra-mPFC administration of AM251, URB597 or URB597 + AM251 on the expression of conditioned fear behaviour in the presence of formalin-evoked nociceptive tone
In the IfL study, there was a significant effect of fear conditioning, treatment and fear conditioning * treatment on the duration of freezing over the course of the 30 min testing period ( Figure 5B ). There was also a significant effect of time, time * fear conditioning, time * treatment and time * fear conditioning * treatment. Further post hoc analysis using Tukey's test revealed that FC VEH-treated rats displayed significantly more freezing compared with NFC VEH-treated rats in the first 20 min of the testing period. Intra-IfL administration of AM251 or URB597 alone significantly attenuated this contextually induced freezing over the first 20 min of the trial and during 10-20 min when the drugs were co-administered as shown in Figure 5B .
In the PrL study, there was a significant effect of fear conditioning but not treatment or fear conditioning * treatment on the duration of freezing over the course of the 30 min testing period ( Figure 6B ). There was also a significant effect of time and time * fear conditioning but not time * treatment or time * fear conditioning * treatment. Further post hoc analysis using Tukey's test revealed that FC VEH-treated rats displayed significantly more freezing compared with NFC VEH-treated rats in the first 10 min of the testing period. Intra-PrL administration of AM251 or URB597, alone or in combination, had no significant effect on the expression of this contextually induced freezing ( Figure 6B ).
In the ACC study, analysis of the results showed a significant effect of fear conditioning but not treatment or fear conditioning * treatment on the duration of freezing over the course of the 30 min testing period. There was also a significant effect of time and time * fear conditioning but not time * treatment or time * fear conditioning * treatment. Further post hoc analysis using Tukey's test revealed that FC VEHtreated rats displayed significantly more freezing compared with NFC VEH-treated rats in the first 10 min of the testing period. Intra-ACC administration of AM251 or URB597, alone or in combination, had no significant effect on the duration of freezing ( Figure 7B ).
Data from these sets of experiments are summarised in Table 3 .
Figure 7
(A) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the ACC on formalin-evoked nociceptive behaviour in rats over the full 30 min testing period subdivided into 10 min time bins. (B) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the ACC on the duration of freezing in formalin-injected rats over the full 30 min testing period, subdivided into 10 min time bins. (C) Effects of fear conditioning and bilateral administration of URB597, AM251 or URB597 + AM251 directly into the ACC on the distance moved (cm) in formalininjected rats over the full 30 min testing period, subdivided into 10 min time bins. . All data are expressed as mean ± SEM. *P < 0.05, significantly different from NFC.
Table 2
Summary of the drug effects on the expression of FCA in rats
IfL
PrL ACC
-, no effect; ↓, attenuated; ↑, enhanced or prolonged.
Effects of fear conditioning and AM251, URB597 or URB597 + AM251 on locomotor activity in formalin-treated rats
In the IfL study, there was no significant effect of fear conditioning, treatment or fear conditioning * treatment on distance moved. There was an effect of time and time * fear conditioning but not time * treatment or time * fear conditioning * treatment. Further post hoc analysis revealed no significant differences between-groupmeans ( Figure 5C ). In the PrL study, there was no significant effect of fear conditioning, treatment or fear conditioning * treatment on distance moved. There was an effect of time and time * fear conditioning but not time * treatment or time * fear conditioning * treatment. Further post hoc analysis revealed no significant between-group differences ( Figure 6C ).
In the ACC study, there was no significant effect of fear conditioning, treatment or fear conditioning * treatment on distance moved ( Figure 7C ). There was an effect of time * fear conditioning but not time, time * treatment or time * fear conditioning * treatment. Further post hoc analysis revealed no significant differences between group means ( Figure 7C ).
Discussion
The data presented here demonstrate for the first time that the endocannabinoid system in the mPFC is an important neural substrate regulating expression of FCA and fear-pain interactions. The results indicate that this regulation occurs in a subregion-specific manner, with the endocannabinoid system in the PrL, IfL and ACC playing distinct and differential modulatory roles in expression of FCA and fear in the presence of nociceptive tone.
Blockade of CB 1 receptors in the PrL with AM251 attenuated FCA with no effects on the expression of formalinevoked nociceptive behaviour per se or on contextually induced freezing in the presence of nociceptive tone. In addition, intra-PrL administration of the FAAH inhibitor URB597 prolonged the expression of FCA in the absence but not the presence of AM251. These findings together suggest that FCA is mediated by endocannabinoids acting at CB 1 receptors within the PrL and suggest that the PrL can be considered as an additional important neural substrate for endocannabinoid-mediated FCA, alongside the ventral hippocampus (Ford et al., 2011) , dorsolateral periaqueductal grey (Olango et al., 2012) and basolateral amygdala (Roche et al., 2007; Rea et al., 2013) . The results of this PrL study also corroborate our previous studies (Finn et al., 2004; Roche et al., 2007; Roche et al., 2010; Rea et al., 2014b) and those of others (Kinscheck et al., 1984; Helmstetter and Fanselow, 1987) , demonstrating that pain-related behaviour in FC animals can be altered independently of the level of fear being expressed in these animals in the presence of nociceptive tone.
In contrast to the PrL, either CB 1 receptor blockade or FAAH inhibition within the IfL attenuated expression of both FCA and contextually induced freezing in the presence of nociceptive tone. Thus, in contrast to the results for the PrL study where the effects of the endocannabinoid system on FCA and fear-related freezing were dissociable, the endocannabinoid system in the IfL appears to modulate FCA and contextually induced freezing in the same direction. It is also interesting that in the IfL, both AM251 and URB597 attenuated FCA and freezing, given the differing mechanisms of action of these drugs (CB 1 receptor blockade vs. FAAH inhibition, respectively). In both the IfL and PrL, AM251 attenuated FCA, suggesting that CB 1 receptors in both of these mPFC subregions mediate FCA. While our data provide the first evidence for a role of the endocannabinoid system in the IfL and PrL in mediating conditioned fear-induced analgesia, previous research has demonstrated a role for the endocannabinoid system in the PrL in the expression of unconditioned fear-induced analgesia (Freitas et al., 2013) . CB 1 receptors in the PrL therefore appear to play a key role in mediating the expression of endogenous analgesia to both conditioned and unconditioned aversive stimuli. However, while the data from our PrL study are compatible with the idea that endocannabinoid-CB 1 receptor signalling mediates FCA, the attenuation of FCA following intra-IfL administration of URB597 is not compatible with the effects of AM251 in the IfL and suggests that activation of a non-CB 1 receptor target by one or more FAAH substrates may instead be mediating the effects of URB597 in the IfL. In this respect, FAAH substrates including AEA, PEA and OEA have been shown to activate a number of non-CB 1 receptors either directly or indirectly (via substrate competition at FAAH) including CB 2 receptors (Felder et al., 1996; Griffin et al., 2000; Petrosino and Di Marzo, 2017) , TRPV1 channels (Smart et al., 2000; De Petrocellis et al., 2001; Di Marzo et al., 2001; Ross et al., 2001) , PPARs (LoVerme et al., 2005; O'Sullivan and Kendall, 2010; Pistis and O'Sullivan, 2017) and GPR55 (Pertwee, 2007; Ryberg et al., 2007; Sharir and Abood, 2010; Kramar et al., 2017) . Further studies should address the potential role of these receptors within the IfL in regulation of fear, pain and FCA.
In our ACC study, in contrast to the results obtained for the PrL and IfL, neither AM251 nor URB597 affected the expression of FCA-or contextually-induced freezing, providing further support for the contention that the endocannabinoid system within the mPFC regulates FCA in a subregion-specific manner. In addition, the data revealed that regardless of the region injected, URB597 and AM251 had no effect on the distance moved, indicating that their effects within the IfL and PrL on FCA-and contextuallyinduced freezing are likely to represent specific effects on Table 3 Summary of the drug effects on the expression of contextually induced freezing in rats
IfL
-, no effect; ↓, attenuated; ↑, enhanced or prolonged. mPFC endocannabinoids and fear-pain interactions nociceptive and fear-related behaviour rather than overt effects on locomotor activity.
One implication of our findings is that the endocannabinoid system within each of these mPFC subregions may be an important factor contributing to their differential regulation of fear-related and pain-related behaviour, which has previously been described. Alterations in endocannabinoid signalling, coupled with differences in circuitry within, and projections to and from, each of these three mPFC subregions (Vertes, 2002; Vertes, 2004; Hoover and Vertes, 2007) , are likely to underlie their different roles in fear, pain and FCA. One of the first reports of specific but differential functions of subregions in the mPFC was by Vidal-Gonzalez et al. (2006) . They found that microstimulation of the PrL enhanced the expression of conditioned fear to a tone and prevented extinction, while microstimulation of the IfL reduced the expression of conditioned fear and microstimulation of the ACC had no effect on either expression or extinction of conditioned fear (Vidal-Gonzalez et al., 2006) . Inactivation of the PrL but not IfL depressed fear responses, while inactivation of the IfL but not PrL impaired the consolidation and retrieval of fear extinction in rats (Laurent and Westbrook, 2009 ). Lesioning (Kim et al., 2013) or pharmacological inactivation (Corcoran and Quirk, 2007; Sierra-Mercado et al., 2011) of the PrL impairs the expression of conditioned fear without affecting extinction, while inactivation of the IfL has no effect on fear expression but impairs the acquisition of extinction as well the extinction memory (Sierra-Mercado et al., 2011) . Fewer studies have compared the respective roles of these mPFC regions in modulating pain. Preconditioning and postconditioning muscimol-mediated inactivation of IfL and PrL had no effect on expression of formalin-evoked pain per se but differentially affected formalin-evoked condition place aversion, which was impaired by PrL, not IfL, inactivation (Jiang et al., 2014) . Similarly, in the present studies, we have observed little or no effect of pharmacological modulation of the endocannabinoid system within these three mPFC subregions on formalin-evoked nociceptive behaviour in the absence of fear under the conditions of testing used here (but see Okine et al., 2016 where test conditions differed and intra-ACC administration of AM251 reduced formalinevoked nociceptive behaviour). Future studies should address whether this differential modulation of FCA is achieved via differential modulation of the pathways connecting these mPFC subregions to downstream components of the descending inhibitory pain pathway, such as the amygdala and PAG, or more locally within the three subregions themselves via alteration of incoming ascending nociceptive information.
In conclusion, the present studies provide new evidence to support a role for the endocannabinoid system within the subregions of the mPFC in the expression of FCA and conditioned fear in the presence of nociceptive tone. Furthermore, our data suggest that endocannabinoidmediated regulation of these behaviours occurs in an mPFC subregion-specific manner. Elucidation of the role of the endocannabinoid system in different subregions of the mPFC in fear-pain interactions may facilitate increased understanding of, and development of new therapeutic approaches for, pain-related and fear-related disorders and their comorbidity.
